Related Experiment Video
Updated: Jun 4, 2026
Assessment of Ovarian Cancer Spheroid Attachment and Invasion of Mesothelial Cells in Real Time
Published on: May 20, 2014
Functional roles of Src and Fgr in ovarian carcinoma
Hye-Sun Kim1, Hee Dong Han, Guillermo N Armaiz-Pena
1Department of Gynecologic Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA.
Purpose:
Src is an attractive target because it is overexpressed in a number of malignancies, including ovarian cancer. However, the effect of Src silencing on other Src family kinases (SFKs) is not known. We hypothesized that other SFK members could compensate for the lack of Src activity.
Experimental Design:
Cell viability after either Src or Fgr silencing was examined in ovarian cancer cell lines by MTT assay. Expression of SFKs after Src silencing in ovarian cancer cells was examined by real-time reverse transcriptase (RT)-PCR. Therapeutic effect of in vivo Src and/or Fgr silencing was examined using siRNA incorporated into chitosan nanoparticles (siRNA/CH-NP). Microvessel density, cell proliferation, and apoptosis markers were determined by immunohistochemical staining in ovarian tumor tissues.
Results:
Src silencing enhanced cytotoxicity of docetaxel in both SKOV3ip1 and HeyA8 cells. In addition, Src silencing using siRNA/CH-NP in combination with docetaxel resulted in significant inhibition of tumor growth compared with control siRNA/CH-NP (81.8% reduction in SKOV3ip1, P = 0.017; 84.3% reduction in HeyA8, P < 0.005). These effects were mediated by decreased tumor cell proliferation and angiogenesis, and increased tumor cell apoptosis. Next, we assessed the effects of Src silencing on other SFK members in ovarian cancer cell lines. Src silencing resulted in significantly increased Fgr levels. Dual Src and Fgr silencing in vitro resulted in increased apoptosis that was mediated by increased caspase and AKT activity. In addition, dual silencing of Src and Fgr in vivo using siRNA/CH-NP resulted in the greatest reduction in tumor growth compared with silencing of either Src or Fgr alone in the HeyA8 model (68.8%, P < 0.05).
Conclusions:
This study demonstrates that, in addition to Src, Fgr plays a biologically significant role in ovarian cancer growth and might represent an important target.
Insights
Silencing Src kinase in ovarian cancer cells enhances chemotherapy effectiveness and reduces tumor growth. Dual silencing of Src and Fgr kinases shows the greatest tumor reduction, highlighting Fgr as a potential therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Src kinase is overexpressed in ovarian cancer, making it a potential therapeutic target.
- The compensatory effects of other Src family kinases (SFKs) after Src inhibition are not well understood.
Purpose of the Study:
- To investigate the impact of Src silencing on ovarian cancer cell viability and response to chemotherapy.
- To explore the compensatory roles of other SFKs, specifically Fgr, following Src inhibition.
- To evaluate the therapeutic efficacy of combined Src and Fgr silencing in ovarian cancer models.
Main Methods:
- Ovarian cancer cell lines were treated with siRNA targeting Src or Fgr, and cell viability was assessed using MTT assays.
- SFK expression levels were analyzed by real-time RT-PCR after Src silencing.
- In vivo studies utilized siRNA encapsulated in chitosan nanoparticles (siRNA/CH-NP) for therapeutic delivery.
- Tumor tissues were analyzed for microvessel density, proliferation, and apoptosis markers via immunohistochemistry.
Main Results:
- Src silencing potentiated docetaxel-induced cytotoxicity in ovarian cancer cells.
- Combined Src silencing with docetaxel significantly inhibited tumor growth, decreasing proliferation and angiogenesis while increasing apoptosis.
- Src silencing led to increased Fgr expression, suggesting a compensatory mechanism.
- Dual silencing of Src and Fgr resulted in enhanced apoptosis in vitro and the most significant tumor growth reduction in vivo.
Conclusions:
- Src plays a critical role in ovarian cancer progression.
- Fgr kinase is also a significant contributor to ovarian cancer growth and may serve as a viable therapeutic target.
- Combined inhibition of Src and Fgr presents a promising strategy for ovarian cancer treatment.
Related Concept Videos
01:20The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
02:38Mitogens and the Cell Cycle
01:03Rous Sarcoma Virus (RSV) and Cancer
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
01:33Cancer-Critical Genes I: Proto-oncogenes
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...